Esophagogastric junction adenocarcinoma: Preoperative chemoradiation or perioperative chemotherapy?

doi:10.5306/wjco.v12.i7.557

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5283)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

296

WORD

126

HTML

2285

Figures (1-1)

250

Tables (1-2)

249

Sum=3206

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

314

Download

507

Sum=821

Publishing Process of This Article

Item

Count

Browse

445

Download

811

Sum=1256

Jul 24, 2021 (publication date) through Sep 18, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Oncol. Jul 24, 2021; 12(7): 557-564
Published online Jul 24, 2021. doi: 10.5306/wjco.v12.i7.557

Open in New Tab Full Size Figure Download Figure

Figure 1 Timeline of neoadjuvant and perioperative therapies in patients with esophagogastric junction cancer. MAGIC: The British Medical Research Council Adjuvant Gastric Infusional Chemotherapy; CROSS: ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study.

Citation: Laxague F, Schlottmann F. Esophagogastric junction adenocarcinoma: Preoperative chemoradiation or perioperative chemotherapy? World J Clin Oncol 2021; 12(7): 557-564
URL: https://www.wjgnet.com/2218-4333/full/v12/i7/557.htm
DOI: https://dx.doi.org/10.5306/wjco.v12.i7.557